Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds SMBC Nikko Downgrades Jounce Therapeutics to Neutral

SMBC Nikko Downgrades Jounce Therapeutics to Neutral

SMBC Nikko analyst David Dai downgrades Jounce Therapeutics (NASDAQ:JNCE) from Outperform to Neutral.

byBenzinga Newsdesk

February 24, 2023

1 minute read

SMBC Nikko analyst David Dai downgrades Jounce Therapeutics (NASDAQ:JNCE) from Outperform to Neutral.

WaveDancer Says On July 8 Entered Into A Common Stock Purchase Agreement And A Registration Rights Agreement With B. Riley Principal Capital To Sell Up To $15M Shares

By Benzinga Newsdesk

July 11, 12:46 PM

-SEC Filing

WAVD

Cybin Inc’s Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results

By Lara Goldstein

January 9, 4:36 PM

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers.

CYBN

$1000 Invested In Valero Energy 10 Years Ago Would Be Worth This Much Today

By Benzinga Insights

October 5, 10:16 AM

Valero Energy (NYSE:VLO) has outperformed the market over the past 10 years by 5.01% on an annualized basis producing an average annual return of 15.0%. Currently, Valero Energy has a market capitalization of $45.70 billion.

VLO